xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05978050</url>
    </required_header>
    <id_info>
      <org_study_id>BPL-Nim-GC-3001</org_study_id>
      <nct_id>NCT05978050</nct_id>
    </id_info>
    <brief_title>Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma</brief_title>
    <acronym>NOTABLE-307</acronym>
    <official_title>Nimotuzumab Combined With Paclitaxel as Second-line Treatment for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma With EGFR Over-expression: A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Biotech Pharmaceutical Co., Ltd.</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Biotech Pharmaceutical Co., Ltd.</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        In order to evaluate the efficacy and safety of nimotuzumab combined with paclitaxel as&#xD;
        second-line treatment for recurrent metastatic gastric or esophagogastric junction&#xD;
        adenocarcinoma with EGFR over-expression, investigators performed a randomized, double-blind,&#xD;
        placebo-controlled phase III clinical trial. Patients will be randomized (1:1) to receive&#xD;
        nimotuzumab plus paclitaxel in the experimental group and placebo plus paclitaxel in the&#xD;
        control group. The primary endpoint of this study was OS, and according to the results of the&#xD;
        RAINBOW-Asia gastric cancer phase III clinical study, the mOS of paclitaxel single-agent&#xD;
        second-line treatment for gastric cancer was 7.92 months, assuming that the mOS increased to&#xD;
        10.92 months after the addition of nimotuzumab, Using the survival module in the PASS15&#xD;
        software, the two-sided test level was set α=0.05, β=0.20, enrolled for 2 years, followed up&#xD;
        for 1.5 years, the dropout rate was 5%, the sample size including interim analysis was 354&#xD;
        cases. The secondary endpoints are progression-free survival (PFS), objective response rate&#xD;
        (ORR), duration of response (DOR), disease control rate (DCR), patient reported outcome&#xD;
        (PRO), and safety.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Study design:&#xD;
  &#xD;
        This study is a prospective, randomized, double-blind, placebo-controlled trial designed to&#xD;
        evaluate the efficacy and safety of nimotuzumab combined with paclitaxel as second-line&#xD;
        treatment for recurrent metastatic gastric or esophagogastric junction adenocarcinoma with&#xD;
        EGFR over-expression.A total of 354 patients with recurrent metastatic gastric or&#xD;
        esophagogastric junction adenocarcinoma with EGFR over-expression are expected to be&#xD;
        enrolled. Patients will be randomized (1:1) to receive nimotuzumab (600 mg for the first&#xD;
        dose, then 400 mg, weekly) plus paclitaxel (80 mg/m2, on day 1, 8 and 15, every 4 weeks as a&#xD;
        cycle) in the experimental group and placebo plus paclitaxel (same as experimental group) in&#xD;
        the control group. The study will be randomized by stratified block randomization,&#xD;
        stratification factors included ECOG PS (0 vs. 1), first-line immunotherapy (yes vs. no), and&#xD;
        EGFR expression status (IHC 2+ vs. 3+). Treatment will continue until disease progression,&#xD;
        intolerance, or patient withdrawal from the trial, and each patient will be followed up until&#xD;
        death, loss to follow-up, or the end of study.&#xD;
  &#xD;
        Quality Assurance plan： According to the GCP's guidelines, sponsors are responsible for using&#xD;
        and maintaining quality assurance and quality control systems in accordance with the&#xD;
        corresponding standard operating procedures (SOPs). The sponsor or sponsor's representative&#xD;
        shall conduct quality control at every stage of data processing to ensure the accuracy,&#xD;
        consistency, completeness and reliability of the data. In addition, the sponsor or its&#xD;
        representative, the appropriate regulatory body, may conduct audits and/or inspections of the&#xD;
        research process. During audits and/or regulatory inspections, authorized sponsor&#xD;
        representatives and relevant regulatory authorities have access to all research-related&#xD;
        documents.&#xD;
  &#xD;
        Data checks:&#xD;
  &#xD;
        Investigators should collect complete participant data as required by the protocol, recorded&#xD;
        in the original record. This study will use an electronic data acquisition (EDC) system, and&#xD;
        the library builder will build an electronic database according to the plan, set up the&#xD;
        corresponding logic verification, and data management personnel will conduct data&#xD;
        verification according to the corresponding verification plan.&#xD;
  &#xD;
        Source data verification:&#xD;
  &#xD;
        The research data will be entered into the eCRF by the researcher or authorized research&#xD;
        center staff. Investigators review the data to ensure the accuracy of all data entered into&#xD;
        the eCRF. The eCRF will be reviewed by the Inspector and assessed for completeness and&#xD;
        consistency, and the Auditor will compare the eCRF with the original documentation to ensure&#xD;
        consistency of critical data. All data entry, correction and modification will be the&#xD;
        responsibility of the researcher or its designee, and the supervisor will not have this&#xD;
        authority. The data in the eCRF is submitted to the data server, and any changes to the data&#xD;
        will be recorded in the audit track, that is, the reason for the change, the operator account&#xD;
        number, the modification time and date will be recorded. If there is a data challenge, the&#xD;
        monitor, medical or data management personnel will issue the challenge in the EDC according&#xD;
        to the corresponding verification plan, and the research center staff will be responsible for&#xD;
        answering the question, and conduct data verification from multiple parties and angles to&#xD;
        ensure data quality. After all data has been entered into the EDC in its entirety, the&#xD;
        monitor has completed the SDV on all data in the EDC, the medical and data administrator has&#xD;
        completed the review of all data in the EDC, and all challenges have been closed, the data&#xD;
        administrator freezes the data.&#xD;
  &#xD;
        Data dictionary:&#xD;
  &#xD;
        The combined medication and medical history will be encoded using the Anatomical,&#xD;
        Therapeutic, and Chemical Taxonomy of Drugs (ATC 2021 and above) and the Regulatory&#xD;
        Activities Medical Dictionary (MedDRA V24.0 and above), respectively.&#xD;
  &#xD;
        Standard Operating Procedures:&#xD;
  &#xD;
        Informed consent approved by the Independent Ethics Committee (IEC)/Institutional Review&#xD;
        Board (IRB) must be obtained prior to carrying out any research-specific procedures.&#xD;
        Potentially eligible subjects will be screened within 4 weeks prior to the first dose, and&#xD;
        after qualified subject screening, they will be enrolled through an interactive web response&#xD;
        system (IWRS). Investigators should collect complete participant data (e.g., laboratory&#xD;
        tests, vital signs, physical examination, electrocardiogram, imaging tests, adverse effects,&#xD;
        quality of life assessment scale evaluation, etc.) as required by the protocol and record&#xD;
        them in the original record.&#xD;
  &#xD;
        Investigators are required to submit a completed eCRF for each participant enrolled in the&#xD;
        study. Study numbers and subject numbers submitted with the eCRF should be carefully verified&#xD;
        and all private information (including subject names) removed or rendered illegible to&#xD;
        protect subject privacy. When researching data entry into eCRF, the system will automatically&#xD;
        add the identity of the data entry user by the ID of the login user. The investigator proves&#xD;
        that it has reviewed the record through an electronic signature record and guarantees the&#xD;
        accuracy of the data in the record. After all data in the EDC is reviewed and all doubts have&#xD;
        been closed, the data is locked and analyzed.&#xD;
  &#xD;
        Adverse events were monitored throughout the study and it was the responsibility of the&#xD;
        investigator to document all AEs observed during the study. From the beginning of the&#xD;
        subject's signing of informed consent to 30 days after the last dose of the investigational&#xD;
        drug, all AEs, regardless of severity and causal relationship with the investigational drug,&#xD;
        need to be recorded in the original data and the corresponding AE page in the eCRF. According&#xD;
        to the relevant regulations of ICH and China GCP (2020 edition), during this study,&#xD;
        investigators should complete the SAE report form provided by the sponsor and report to the&#xD;
        sponsor in writing within 24 hours after learning of SAE or relevant new follow-up&#xD;
        information.&#xD;
  &#xD;
        Sample size:&#xD;
  &#xD;
        The primary endpoint of this study was OS, and according to the results of the RAINBOW-Asia&#xD;
        gastric cancer phase III clinical study, the mOS of paclitaxel single-agent second-line&#xD;
        treatment for gastric cancer was 7.92 months, assuming that the mOS increased to 10.92 months&#xD;
        after the addition of nimotuzumab, and an interim analysis was set up during the trial. Using&#xD;
        the survival module in the PASS15 software, the two-sided test level was set α=0.05, β=0.20,&#xD;
        enrolled for 2 years, followed up for 1.5 years, the dropout rate was 5%, the single-stage&#xD;
        sample size was 354 cases, and the required sample size for each group was 177.&#xD;
  &#xD;
        Plan for missing data:&#xD;
  &#xD;
        For participants who had not reported death at the time of analysis, the last known surviving&#xD;
        follow-up date was used as the censoring date. For subjects who have not yet progressed, the&#xD;
        date of the last radiographic evaluation is used as the date of censoring. For participants&#xD;
        who had not undergone tumour assessment after baseline, the date of randomisation was used as&#xD;
        the date of censoring.&#xD;
  &#xD;
        Statistical analysis plan:&#xD;
  &#xD;
        The main overall survival (OS) analysis will be performed when 306 death events occur,&#xD;
        optimality test and blind sample size adjustment will be performed when 50% of death events&#xD;
        occur.&#xD;
  &#xD;
        The primary endpoint of this study was mOS. OS is the time between the date of randomization&#xD;
        and death from any cause. A stratified log-rank test was used to compare OS in the&#xD;
        nilotuzumab plus paclitaxel and placebo plus paclitaxel group at a bilateral significance&#xD;
        level of 0.05. The Kaplan-Meier (KM) method was used to estimate the OS of each treatment&#xD;
        group, and the Kaplan-Meier curve was plotted to show the survival difference description.&#xD;
        Efficacy estimates of OS will be expressed by risk ratios (HR) estimated by the hierarchical&#xD;
        Cox proportional hazards model and their 95% confidence intervals.&#xD;
  &#xD;
        Secondary endpoints: PFS, ORR, DOR, DCR，PRO and safety. The Kaplan-Meier (KM) method was used&#xD;
        to estimate the PFS of each treatment group, and the Kaplan-Meier curve was plotted to show&#xD;
        the difference description. The stratification factors are the same as for OS analysis.&#xD;
        Efficacy estimates of PFS will be expressed by risk ratios (HR) estimated by the hierarchical&#xD;
        Cox proportional hazards model and their 95% confidence intervals. The Clopper-Pearson exact&#xD;
        probability method was used to calculate the ORR and DCR estimates and their 95% confidence&#xD;
        intervals for each treatment group, respectively. The Cochran-Mantel-Haenszel (CMH) method&#xD;
        was used to calculate the odds ratio and its 95% confidence interval and p. The&#xD;
        stratification factors used in the CMH test are the same as in the OS analysis. If the number&#xD;
        of objective remission or disease control cases is insufficient to support the CMH test,&#xD;
        stratified precision testing is considered and precise confidence intervals for odds ratios&#xD;
        are calculated. DOR is only available for participants with objective response (CR/PR) for&#xD;
        descriptive analysis of TOR. Results will be shown using the Kaplan-Meier method for each&#xD;
        treatment group to estimate the median DOR and the distribution curve.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 1, 2023</start_date>
    <completion_date type="Anticipated">March 1, 2026</completion_date>
    <primary_completion_date type="Anticipated">March 1, 2026</primary_completion_date>
    <phase>Phase 3</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Overall survival</measure>
      <time_frame>through study completion, an average of 18 months</time_frame>
      <description>The time between the date of randomization and death from any cause .</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>progression-free survival</measure>
      <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</time_frame>
      <description>The time between the date of randomization and the date of PD or death when PD was first recorded, whichever occurs first</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>objective response rate</measure>
      <time_frame>Assessment is performed every 4 weeks for the first 3 months, every 8 weeks to 12 months thereafter, and every 3 months thereafter until disease progression ,assessed up to 12 months</time_frame>
      <description>The optimal total response (BOR) is the incidence of complete response (CR) or partial response (PR).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>DCR</measure>
      <time_frame>Assessment is performed every 4 weeks for the first 3 months, every 8 weeks to 12 months thereafter, and every 3 months thereafter until disease progression,assessed up to 12 months</time_frame>
      <description>CR+PR+SD</description>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">354</enrollment>
    <condition>Gastric or Esophagogastric Junction Adenocarcinoma</condition>
    <arm_group>
      <arm_group_label>nimotuzumab</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Participants received nimotuzumab injection 600 mg for the first time, followed by 400 mg once a week until disease progression or inability to tolerate or withdrawal from the trial; At the same time, in combination with paclitaxel 80 mg/m2, it was administered on days 1, 8 and 15 of each treatment cycle (4 weeks) until the disease progressed or could not be tolerated or withdrew from the trial.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>placebo</arm_group_label>
      <arm_group_type>Placebo Comparator</arm_group_type>
      <description>Participants received placebo 600 mg for the first time, followed by 400 mg once a week until disease progression or inability to tolerate or withdrawal from the trial; At the same time, in combination with paclitaxel 80 mg/m2, it was administered on days 1, 8 and 15 of each treatment cycle (4 weeks) until the disease progressed or could not be tolerated or withdrew from the trial.</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>nimotuzumab plus paclitaxel</intervention_name>
      <description>Nimotuzumab injection: 50mg/10ml/stick Paclitaxel: 30mg/5ml/stick</description>
      <arm_group_label>nimotuzumab</arm_group_label>
      <other_name>Combined with chemotherapy</other_name>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>placebo plus paclitaxel</intervention_name>
      <description>placebo: 50mg/10ml/stick Paclitaxel: 30mg/5ml/stick</description>
      <arm_group_label>placebo</arm_group_label>
      <other_name>chemotherapy alone</other_name>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  1. Age: 18-75 years old (including boundary value), male or female;&#xD;
  &#xD;
            -  2. The physical status score ECOG is 0-1;&#xD;
  &#xD;
            -  3. Histopathologically or cytologically confirmed gastric or esophagogastric junction&#xD;
               adenocarcinoma;&#xD;
  &#xD;
            -  4. Recurrent metastatic disease, previous treatment with first-line standard&#xD;
               chemotherapy regimens (including platinum-containing and/or fluorouracil regimens)&#xD;
               (recurrence or metastasis during adjuvant therapy or within 6 months after completion&#xD;
               is considered first-line therapy), or received anti-HER2 therapy, or received&#xD;
               immunotherapy, and has been confirmed by the investigator or has a clear disease&#xD;
               progression in the medical history;&#xD;
  &#xD;
            -  5. At least one evaluable tumor lesion according to the RECIST version 1.1 evaluation&#xD;
               criteria;&#xD;
  &#xD;
            -  6. Detection of primary or metastatic lesions during the screening period (when&#xD;
               multiple specimens exist at the same time, the bulk specimen is preferred over the&#xD;
               biopsy specimen, and the metastasis is preferred over the primary lesion) tissue is&#xD;
               determined to be EGFR high expression (IHC2+ or IHC3+);&#xD;
  &#xD;
            -  7. Estimated survival≥ 12 weeks;&#xD;
  &#xD;
            -  8. Have proper organ function, defined as:Total bilirubin ≤ 1.5 times the upper normal&#xD;
               limit (ULN); glutamyltransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5 times&#xD;
               ULN in the absence of liver metastases; ALT or AST ≤ 5 times ULN in the presence of&#xD;
               liver metastases;Serum creatinine level≤ 1.5 times ULN; neutrophil count ≥1.5×109/L;&#xD;
               WBC count≥ 3.0×109/L; platelets≥ 100×109/L; Hemoglobin≥ 90g/L;&#xD;
  &#xD;
            -  9. Patients of childbearing age and their spouses are willing to use contraception;&#xD;
  &#xD;
            -  10. Women of potential fertility have negative serum hCG within 72 hours prior to&#xD;
               randomization (postmenopausal women with amenorrhea for at least 12 months are&#xD;
               considered infertile, and women who are known to have undergone tubal ligation are not&#xD;
               required to undergo a pregnancy test);&#xD;
  &#xD;
            -  11. The subject understands and complies with the study process, voluntarily&#xD;
               participates, and signs the informed consent form.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  1. Received the following treatments before this study:&#xD;
  &#xD;
                 1. The disease has progressed after previous paclitaxel chemotherapy or molecular&#xD;
                    targeted drug (anti-EGFR antibody) treatment, or received paclitaxel chemotherapy&#xD;
                    or molecular targeted drug (anti-EGFR antibody) treatment within 4 weeks before&#xD;
                    randomization;&#xD;
  &#xD;
                 2. Within 4 weeks before randomization or participating in other&#xD;
                    therapeutic/intervention clinical trials or receiving combined treatment&#xD;
                    prohibited by the protocol;&#xD;
  &#xD;
            -  2. Received major surgical treatment, incision biopsy (such as laparotomy) or obvious&#xD;
               traumatic injury within 4 weeks before randomization;&#xD;
  &#xD;
            -  3. Brain metastases or meningeal metastases;&#xD;
  &#xD;
            -  4. Has a history of malignant tumors other than gastric adenocarcinoma or&#xD;
               esophagogastric junction adenocarcinoma (except for cured cervical carcinoma in situ&#xD;
               or skin basal cell carcinoma and other malignant tumors that have been cured for 5&#xD;
               years);&#xD;
  &#xD;
            -  5. Known to have suffered from severe bleeding disorders (such as severe&#xD;
               gastrointestinal bleeding) and vasculitis within 3 months before randomization;&#xD;
  &#xD;
            -  6. Known to be accompanied by other serious diseases, including but not limited to:&#xD;
  &#xD;
                 1. Refractory congestive heart failure (NYHA classification III or IV, see Appendix&#xD;
                    2), unstable angina, poorly controlled arrhythmia, uncontrolled moderate or high&#xD;
                    blood pressure (SBP&gt;160mmHg or DBP&gt;100mmHg );&#xD;
  &#xD;
                 2. Uncontrolled diabetes;&#xD;
  &#xD;
                 3. Mental illness that affects informed consent and/or protocol compliance;&#xD;
  &#xD;
                 4. There are serious diseases that other researchers believe are not suitable for&#xD;
                    participating in this study;&#xD;
  &#xD;
            -  7. Known allergies or contraindications to anti-EGFR antibody preparations, paclitaxel&#xD;
               and other components;&#xD;
  &#xD;
            -  8. Patients who have previously used immune checkpoint inhibitors (such as anti-PD-1,&#xD;
               anti-PD-L1, anti-CTLA-4 antibodies), such as the following adverse events related to&#xD;
               immune checkpoint inhibitors and have not recovered to grade 1 And below, not suitable&#xD;
               for inclusion: Grade ≥3 ocular adverse events, abnormal liver function in line with&#xD;
               Hy's Law standard adverse events, ≥3 neurological toxicity, ≥3 grade colitis, ≥3 grade&#xD;
               renal toxicity;&#xD;
  &#xD;
            -  9. Those who are known to have third space effusion (including a large amount of&#xD;
               pleural effusion or ascites) that cannot be controlled by drainage or other methods;&#xD;
  &#xD;
            -  10. Known NCI CTC grade 2-4 peripheral neuropathy;&#xD;
  &#xD;
            -  11. Known history of primary or secondary immunodeficiency or current active primary&#xD;
               or secondary immunodeficiency;&#xD;
  &#xD;
            -  12. Patients with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) DNA&#xD;
               ≥ 1000 IU/ml or hepatitis C virus (HCV) RNA positive (inactive hepatitis B surface&#xD;
               antigen carriers, treated And stable hepatitis B patients [HBV DNA &lt;1000 IU/ml and&#xD;
               cured hepatitis C patients can be selected]); Treponema pallidum antibody positive or&#xD;
               human immunodeficiency virus antibody positive or any uncontrolled infection By;&#xD;
  &#xD;
            -  13. Women of childbearing age who are pregnant, breast-feeding, planning to become&#xD;
               pregnant, or who have not taken reliable birth control measures and men in the&#xD;
               sexually active period who are unwilling to take birth control measures during the&#xD;
               study period and within 3 months after the last medication, and during the&#xD;
               above-mentioned specified time Sperm donors;&#xD;
  &#xD;
            -  14. Any medical, psychiatric or other condition or situation that the investigator&#xD;
               believes that the subject's participation in this clinical research may have a&#xD;
               negative impact on the safety of the subject or the reliability of the research data.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <gender_based>Yes</gender_based>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>75 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>ruihua Xu, Doctor</last_name>
      <role>Principal Investigator</role>
      <affiliation>Sun Yat-sen University</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>xijuan Song</last_name>
      <phone>010-51571020</phone>
      <email>songxijuan@biotechplc.com</email>
    </overall_contact>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>July 20, 2023</study_first_submitted>
    <study_first_submitted_qc>August 3, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 7, 2023</study_first_posted>
    <last_update_submitted>August 3, 2023</last_update_submitted>
    <last_update_submitted_qc>August 3, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 7, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Adenocarcinoma</mesh_term>
    </condition_browse>
    <intervention_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Paclitaxel</mesh_term>
      <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
      <mesh_term>Nimotuzumab</mesh_term>
    </intervention_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05978050
  org study id: BPL-Nim-GC-3001
  nct id: NCT05978050
  lead sponsor: 
  has dmc: Yes
  is fda regulated drug: No
  is fda regulated device: No
  In order to evaluate the efficacy and safety of nimotuzumab combined with paclitaxel as
        second-line treatment for recurrent metastatic gastric or esophagogastric junction
        adenocarcinoma with EGFR over-expression, investigators performed a randomized, double-blind,
        placebo-controlled phase III clinical trial. Patients will be randomized (1:1) to receive
        nimotuzumab plus paclitaxel in the experimental group and placebo plus paclitaxel in the
        control group. The primary endpoint of this study was OS, and according to the results of the
        RAINBOW-Asia gastric cancer phase III clinical study, the mOS of paclitaxel single-agent
        second-line treatment for gastric cancer was 7.92 months, assuming that the mOS increased to
        10.92 months after the addition of nimotuzumab, Using the survival module in the PASS15
        software, the two-sided test level was set α=0.05, β=0.20, enrolled for 2 years, followed up
        for 1.5 years, the dropout rate was 5%, the sample size including interim analysis was 354
        cases. The secondary endpoints are progression-free survival (PFS), objective response rate
        (ORR), duration of response (DOR), disease control rate (DCR), patient reported outcome
        (PRO), and safety.
  Study design:
  
        This study is a prospective, randomized, double-blind, placebo-controlled trial designed to
        evaluate the efficacy and safety of nimotuzumab combined with paclitaxel as second-line
        treatment for recurrent metastatic gastric or esophagogastric junction adenocarcinoma with
        EGFR over-expression.A total of 354 patients with recurrent metastatic gastric or
        esophagogastric junction adenocarcinoma with EGFR over-expression are expected to be
        enrolled. Patients will be randomized (1:1) to receive nimotuzumab (600 mg for the first
        dose, then 400 mg, weekly) plus paclitaxel (80 mg/m2, on day 1, 8 and 15, every 4 weeks as a
        cycle) in the experimental group and placebo plus paclitaxel (same as experimental group) in
        the control group. The study will be randomized by stratified block randomization,
        stratification factors included ECOG PS (0 vs. 1), first-line immunotherapy (yes vs. no), and
        EGFR expression status (IHC 2+ vs. 3+). Treatment will continue until disease progression,
        intolerance, or patient withdrawal from the trial, and each patient will be followed up until
        death, loss to follow-up, or the end of study.
  
        Quality Assurance plan： According to the GCP's guidelines, sponsors are responsible for using
        and maintaining quality assurance and quality control systems in accordance with the
        corresponding standard operating procedures (SOPs). The sponsor or sponsor's representative
        shall conduct quality control at every stage of data processing to ensure the accuracy,
        consistency, completeness and reliability of the data. In addition, the sponsor or its
        representative, the appropriate regulatory body, may conduct audits and/or inspections of the
        research process. During audits and/or regulatory inspections, authorized sponsor
        representatives and relevant regulatory authorities have access to all research-related
        documents.
  
        Data checks:
  
        Investigators should collect complete participant data as required by the protocol, recorded
        in the original record. This study will use an electronic data acquisition (EDC) system, and
        the library builder will build an electronic database according to the plan, set up the
        corresponding logic verification, and data management personnel will conduct data
        verification according to the corresponding verification plan.
  
        Source data verification:
  
        The research data will be entered into the eCRF by the researcher or authorized research
        center staff. Investigators review the data to ensure the accuracy of all data entered into
        the eCRF. The eCRF will be reviewed by the Inspector and assessed for completeness and
        consistency, and the Auditor will compare the eCRF with the original documentation to ensure
        consistency of critical data. All data entry, correction and modification will be the
        responsibility of the researcher or its designee, and the supervisor will not have this
        authority. The data in the eCRF is submitted to the data server, and any changes to the data
        will be recorded in the audit track, that is, the reason for the change, the operator account
        number, the modification time and date will be recorded. If there is a data challenge, the
        monitor, medical or data management personnel will issue the challenge in the EDC according
        to the corresponding verification plan, and the research center staff will be responsible for
        answering the question, and conduct data verification from multiple parties and angles to
        ensure data quality. After all data has been entered into the EDC in its entirety, the
        monitor has completed the SDV on all data in the EDC, the medical and data administrator has
        completed the review of all data in the EDC, and all challenges have been closed, the data
        administrator freezes the data.
  
        Data dictionary:
  
        The combined medication and medical history will be encoded using the Anatomical,
        Therapeutic, and Chemical Taxonomy of Drugs (ATC 2021 and above) and the Regulatory
        Activities Medical Dictionary (MedDRA V24.0 and above), respectively.
  
        Standard Operating Procedures:
  
        Informed consent approved by the Independent Ethics Committee (IEC)/Institutional Review
        Board (IRB) must be obtained prior to carrying out any research-specific procedures.
        Potentially eligible subjects will be screened within 4 weeks prior to the first dose, and
        after qualified subject screening, they will be enrolled through an interactive web response
        system (IWRS). Investigators should collect complete participant data (e.g., laboratory
        tests, vital signs, physical examination, electrocardiogram, imaging tests, adverse effects,
        quality of life assessment scale evaluation, etc.) as required by the protocol and record
        them in the original record.
  
        Investigators are required to submit a completed eCRF for each participant enrolled in the
        study. Study numbers and subject numbers submitted with the eCRF should be carefully verified
        and all private information (including subject names) removed or rendered illegible to
        protect subject privacy. When researching data entry into eCRF, the system will automatically
        add the identity of the data entry user by the ID of the login user. The investigator proves
        that it has reviewed the record through an electronic signature record and guarantees the
        accuracy of the data in the record. After all data in the EDC is reviewed and all doubts have
        been closed, the data is locked and analyzed.
  
        Adverse events were monitored throughout the study and it was the responsibility of the
        investigator to document all AEs observed during the study. From the beginning of the
        subject's signing of informed consent to 30 days after the last dose of the investigational
        drug, all AEs, regardless of severity and causal relationship with the investigational drug,
        need to be recorded in the original data and the corresponding AE page in the eCRF. According
        to the relevant regulations of ICH and China GCP (2020 edition), during this study,
        investigators should complete the SAE report form provided by the sponsor and report to the
        sponsor in writing within 24 hours after learning of SAE or relevant new follow-up
        information.
  
        Sample size:
  
        The primary endpoint of this study was OS, and according to the results of the RAINBOW-Asia
        gastric cancer phase III clinical study, the mOS of paclitaxel single-agent second-line
        treatment for gastric cancer was 7.92 months, assuming that the mOS increased to 10.92 months
        after the addition of nimotuzumab, and an interim analysis was set up during the trial. Using
        the survival module in the PASS15 software, the two-sided test level was set α=0.05, β=0.20,
        enrolled for 2 years, followed up for 1.5 years, the dropout rate was 5%, the single-stage
        sample size was 354 cases, and the required sample size for each group was 177.
  
        Plan for missing data:
  
        For participants who had not reported death at the time of analysis, the last known surviving
        follow-up date was used as the censoring date. For subjects who have not yet progressed, the
        date of the last radiographic evaluation is used as the date of censoring. For participants
        who had not undergone tumour assessment after baseline, the date of randomisation was used as
        the date of censoring.
  
        Statistical analysis plan:
  
        The main overall survival (OS) analysis will be performed when 306 death events occur,
        optimality test and blind sample size adjustment will be performed when 50% of death events
        occur.
  
        The primary endpoint of this study was mOS. OS is the time between the date of randomization
        and death from any cause. A stratified log-rank test was used to compare OS in the
        nilotuzumab plus paclitaxel and placebo plus paclitaxel group at a bilateral significance
        level of 0.05. The Kaplan-Meier (KM) method was used to estimate the OS of each treatment
        group, and the Kaplan-Meier curve was plotted to show the survival difference description.
        Efficacy estimates of OS will be expressed by risk ratios (HR) estimated by the hierarchical
        Cox proportional hazards model and their 95% confidence intervals.
  
        Secondary endpoints: PFS, ORR, DOR, DCR，PRO and safety. The Kaplan-Meier (KM) method was used
        to estimate the PFS of each treatment group, and the Kaplan-Meier curve was plotted to show
        the difference description. The stratification factors are the same as for OS analysis.
        Efficacy estimates of PFS will be expressed by risk ratios (HR) estimated by the hierarchical
        Cox proportional hazards model and their 95% confidence intervals. The Clopper-Pearson exact
        probability method was used to calculate the ORR and DCR estimates and their 95% confidence
        intervals for each treatment group, respectively. The Cochran-Mantel-Haenszel (CMH) method
        was used to calculate the odds ratio and its 95% confidence interval and p. The
        stratification factors used in the CMH test are the same as in the OS analysis. If the number
        of objective remission or disease control cases is insufficient to support the CMH test,
        stratified precision testing is considered and precise confidence intervals for odds ratios
        are calculated. DOR is only available for participants with objective response (CR/PR) for
        descriptive analysis of TOR. Results will be shown using the Kaplan-Meier method for each
        treatment group to estimate the median DOR and the distribution curve.
  allocation: Randomized
  intervention model: Parallel Assignment
  primary purpose: Treatment
  masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  measure: Overall survival
  time frame: through study completion, an average of 18 months
  description: The time between the date of randomization and death from any cause .
  measure: progression-free survival
  time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
  description: The time between the date of randomization and the date of PD or death when PD was first recorded, whichever occurs first
  measure: objective response rate
  time frame: Assessment is performed every 4 weeks for the first 3 months, every 8 weeks to 12 months thereafter, and every 3 months thereafter until disease progression ,assessed up to 12 months
  description: The optimal total response (BOR) is the incidence of complete response (CR) or partial response (PR).
  measure: DCR
  time frame: Assessment is performed every 4 weeks for the first 3 months, every 8 weeks to 12 months thereafter, and every 3 months thereafter until disease progression,assessed up to 12 months
  description: CR+PR+SD
  arm group label: nimotuzumab
  arm group type: Experimental
  description: Participants received nimotuzumab injection 600 mg for the first time, followed by 400 mg once a week until disease progression or inability to tolerate or withdrawal from the trial; At the same time, in combination with paclitaxel 80 mg/m2, it was administered on days 1, 8 and 15 of each treatment cycle (4 weeks) until the disease progressed or could not be tolerated or withdrew from the trial.
  arm group label: placebo
  arm group type: Placebo Comparator
  description: Participants received placebo 600 mg for the first time, followed by 400 mg once a week until disease progression or inability to tolerate or withdrawal from the trial; At the same time, in combination with paclitaxel 80 mg/m2, it was administered on days 1, 8 and 15 of each treatment cycle (4 weeks) until the disease progressed or could not be tolerated or withdrew from the trial.
  intervention type: Drug
  intervention name: nimotuzumab plus paclitaxel
  description: Nimotuzumab injection: 50mg/10ml/stick Paclitaxel: 30mg/5ml/stick
  arm group label: nimotuzumab
  other name: Combined with chemotherapy
  intervention type: Drug
  intervention name: placebo plus paclitaxel
  description: placebo: 50mg/10ml/stick Paclitaxel: 30mg/5ml/stick
  arm group label: placebo
  other name: chemotherapy alone
  criteria: 
  gender: All
  gender based: Yes
  minimum age: 18 Years
  maximum age: 75 Years
  healthy volunteers: No
  last name: ruihua Xu, Doctor
  role: Principal Investigator
  affiliation: Sun Yat-sen University
  last name: xijuan Song
  phone: 010-51571020
  email: songxijuan@biotechplc.com
  responsible party type: Sponsor
  mesh term: Adenocarcinoma
  mesh term: Paclitaxel
  mesh term: Albumin-Bound Paclitaxel
  mesh term: Nimotuzumab
  sharing ipd: No